文献速递淋巴瘤

纳武利尤单抗治疗不适合或自体移植失败的复发/难治性弥漫大B细胞淋巴瘤:单臂II期研究

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
PubMed 文献 · J Clin Oncol · 2019-01-08

这项单臂II期开放标签研究评估了纳武利尤单抗(3 mg/kg 每2周)在121例不适合自体造血干细胞移植(auto-HCT)或auto-HCT失败的复发/难治性弥漫大B细胞淋巴瘤(DLBCL)患者中的疗效与安全性。auto-HCT失败队列(n=87)客观缓解率为10%,auto-HCT不适合队列(n=34)为3%。纳武利尤单抗单药安全性良好但总体缓解率低,9p24.1基因改变在DLBCL中不常见。

要点

  • auto-HCT失败队列客观缓解率10%,auto-HCT不适合队列3%。
  • auto-HCT失败队列中3例完全缓解者均获持久缓解(≥11、≥14、17个月)。
  • 治疗相关3-4级不良事件发生率24%,最常见为中性粒细胞减少(4%)。

核心结论

  • 纳武利尤单抗单药安全性良好,但在不适合auto-HCT或auto-HCT失败的DLBCL患者中总体缓解率低。
  • 9p24.1基因改变在DLBCL中不常见。

研究设计与样本

  • II期、开放标签、单臂研究,纳入121例不适合auto-HCT或auto-HCT失败的复发/难治性DLBCL患者。
  • 患者接受纳武利尤单抗3 mg/kg 每2周,同时评估疗效、安全性及9p24.1基因改变。

主要发现

  • auto-HCT失败队列(n=87)中位接受4剂纳武利尤单抗,auto-HCT不适合队列(n=34)中位接受3剂。
  • auto-HCT失败队列中位随访9个月,独立评估客观缓解率10%,中位缓解持续时间11个月。
  • auto-HCT不适合队列中位随访6个月,独立评估客观缓解率3%,中位缓解持续时间8个月。
  • auto-HCT失败队列中位无进展生存期1.9个月、总生存期12.2个月;auto-HCT不适合队列分别为1.4个月和5.8个月。
  • auto-HCT失败队列中3例完全缓解(占该队列3%)均获持久缓解(≥11、≥14、17个月)。

关键数值与推荐

  • 治疗相关3-4级不良事件发生于24%的患者,最常见为中性粒细胞减少(4%)、血小板减少(3%)和脂肪酶升高(3%)。
  • 所有可评估9p24.1分析的样本中,16%显示低水平拷贝数增加,3%显示扩增。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune surveillance. In the current study, we evaluated the efficacy and safety of programmed death-1 blockade by nivolumab in patients with relapsed/refractory DLBCL. METHODS: In this phase II, open-label study, patients with relapsed/refractory DLBCL who were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had experienced failure with auto-HCT received nivolumab 3 mg/kg every 2 weeks. We assessed the efficacy and safety of nivolumab as well as genetic alterations of 9p24.1. RESULTS: Among 121 treated patients, patients in the auto-HCT-failed cohort (n = 87) received a median of four nivolumab doses and a median of three doses were administered to those in the auto-HCT-ineligible cohort (n = 34). At a median follow-up of 9 months in the auto-HCT-failed cohort and 6 months in the auto-HCT-ineligible cohort, independently assessed objective response rates were 10% and 3%, and median durations of response were 11 and 8 months, respectively. Median progression-free survival and overall survival were 1.9 and 12.2 months in the auto-HCT-failed cohort and 1.4 and 5.8 months in the auto-HCT-ineligible cohort respectively. All three patients with complete remission-3% of the auto-HCT-failed cohort-had durable response (11 or more, 14 or more, and 17 months). Treatment-related grade 3 and 4 adverse events were reported in 24% of patients. The most common were neutropenia (4%), thrombocytopenia (3%), and increased lipase (3%). Of all evaluable samples for 9p24.1 analysis, 16% exhibited low-level copy gain and 3% had amplification. CONCLUSION: Nivolumab monotherapy is associated with a favorable safety profile but a low overall response rate among patients with DLBCL who are ineligible for auto-HCT or who experienced failure with auto-HCT. Genetic alterations of 9p24.1 are infrequent in DLBCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. J Clin Oncol. 2019. PMID: 30620669. doi:10.1200/JCO.18.00766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。